Solventum Receives FDA Clearance for Combined Use of Wound Care Technologies

05:56 PM EDT, 10/19/2026 (MT Newswires) -- Solventum (SOLV) said late Monday it received 510(k) clearance from the US Food and Drug Administration for the combined use of Restrata synthetic electrospun fiber matrix and V.A.C. negative pressure wound therapy to support active wound healing. Restrata matrix provides structural support for soft tissue repair, while V.A.C. Therapy helps create an environment that supports tissue integration. Their combined use may allow for fewer dressing changes and a more predictable workflow for care teams, according to a statement.